BriaCell Therapeutics Corp BCTX 深 沪
交易中 10-06 11:18:26 美东时间
3.99
-0.190
-4.55%
华盛通- 最 高4.43
- 今 开4.20
- 成交量 3.39万股
- 最 低 3.42
- 昨 收 4.18
- 总市值 6.19万
- 52周最高 14.68
- 市盈率 静 --
- 换手率 218.33%
- 52周最低 2.60
- 委 比 -13.31%
- 总股本 1.55万
- 历史最高 1860.5799
- 量 比 1.47
- 振 幅 24.16%
- 历史最低 2.60
- 每 手 1
- 风险率 3.12%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多BriaCell Therapeutics\ Pivotal Phase 3 Bria-ABC Trial Enrolls 230 Participants
BriaCell Therapeutics Corp. (NASDAQ:BCTX, BCTXL)) (TSX:BCT) ("BriaCell" or the "Company"), a clinical-stage biotechnology company developing novel immunotherapies to transform cancer care, announces that its pivotal
05-12 19:32
Nasdaq Falls Over 100 Points; Bank of America Posts Upbeat Earnings
U.S. stocks traded lower this morning, with the Nasdaq Composite falling more t...
01-14 22:40
BriaCell Therapeutics' Unit Partners With Research.AI To Design Anti-Cancer Isoform-selective Kinase Inhibitors
BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW, BCTXZ) (TSX:BCT) ("BriaCell" or the "Company"), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, has announces that
2025-11-20 20:36
BriaCell Announces Virtual Investor Presentations on Thursday, June 12 and Thursday, June 26
BriaCell Therapeutics Corp. announces virtual investor presentations on June 12 and June 26, 2025, at 12:00 PM EDT. Interested parties can register via the provided links. The company focuses on developing novel cancer immunotherapies.
2025-06-04 11:30
BriaCell Reports Robust Overall Survival and Clinical Benefit Data at ASCO 2025
BriaCell Therapeutics showcases promising Phase 2 data for Bria-IMT in metastatic breast cancer at 2025 ASCO. The treatment demonstrated a median overall survival of 17.3 months, with significant clinical benefits across breast cancer subtypes. No treatment-related discontinuations were reported. The Phase 3 pivotal trial is ongoing to further confirm these results.
2025-06-02 11:30
BriaCell Bria-OTS™ Phase 1/2 Study Clears Safety Evaluation; Doses First Patient in Combination with Checkpoint Inhibitor
Bria-OTS has cleared its Phase 1/2 monotherapy safety evaluation and transitioned to combination therapy with a checkpoint inhibitor in metastatic breast cancer. The first patient remains on the study with resolved lung metastasis, and Bria-OTS+ is being evaluated for broader cancer applications.
2025-05-27 11:30
Nasdaq Surges Over 200 Points; US Crude Oil Stocks Increase
U.S. stocks traded mixed toward the end of trading, with the Nasdaq Composite g...
2024-09-12 02:30
BriaCell Therapeutics Announces $8.5M Best-Efforts Offering Of 12.325M Common Shares At A Price Of $0.69/Share
BriaCell Therapeutics Corp. (NASDAQ:BCTX, BCTXW)))) (TSX:BCT) ("BriaCell" or the "Company"), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, today announced the
2024-09-12 00:14
Crude Oil Surges 2.5%; Rentokil Initial Shares Plunge
U.S. stocks traded mostly lower midway through trading, with the S&P 500 fa...
2024-09-12 00:13
Why Is Breast Cancer-Focused BriaCell Therapeutics Stock Trading Over 100% On Wednesday
BriaCell Therapeutics stock rises on positive Phase 2 trial results showing improved survival in late-stage metastatic breast cancer patients treated with Bria-IMT and an immune checkpoint inhibitor.
2024-09-11 23:08
